{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:01:33Z","timestamp":1791669693319,"version":"4.3.4"},"reference-count":89,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec id=\"ab-drv260001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Psoriasis is a chronic immune-mediated disease associated with cardiovascular, metabolic, musculoskeletal, psychiatric, hepatic, kidney, and pulmonary comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved by the US Food and Drug Administration for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction\u2013associated steatohepatitis\u2014conditions common in psoriasis. Emerging evidence suggests GLP-1 RAs and dual glucose-dependent insulinotropic polypeptide\/GLP-1 agonists may improve psoriatic skin disease, partly through immune modulation. If confirmed in larger randomized clinical trials, GLP-1\u2013based therapies may offer an opportunity to address both cutaneous disease and cardiometabolic comorbidities. This primer from the US National Psoriasis Foundation Medical Board sought to provide an evidence-informed narrative synthesis and practical considerations to introduce dermatologists to GLP-1 RAs for psoriasis treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-drv260001-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>GLP-1 RAs have been associated with reductions in Psoriasis Area and Severity Index (PASI) scores, particularly in patients with obesity or type 2 diabetes. Studies report relative PASI reductions ranging from approximately 40% to 80% with parallel quality-of-life gains, although most of these studies are small (7-48 patients), short term (\u22646 months), and lack a control group. Semaglutide and liraglutide have been associated with reductions in C-reactive protein, interleukin-6, lipids, and visceral adiposity. In small, translational cohorts, PASI improvement has been correlated with reductions in superficial adiposity and dermal \u03b3\u03b4 T-cell density. GLP-1 RAs combine safely with methotrexate, cyclosporine, and biologics. Adverse effects are mainly transient gastrointestinal symptoms; pancreatitis and gallbladder events are rare. Early data show both metabolic and immunomodulatory benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-drv260001-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This review found that GLP-1\u2013based therapies target shared metabolic and inflammatory pathways in psoriasis. Current evidence supports consideration of adjunctive use in selected patients with metabolic comorbidities, although definitive conclusions await larger randomized clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.0859","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:30:55Z","timestamp":1777476655000},"page":"619","source":"Crossref","is-referenced-by-count":9,"title":["The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis"],"prefix":"10.1001","volume":"162","author":[{"given":"Samip","family":"Sheth","sequence":"first","affiliation":[{"name":"Department of Dermatology and Department of Internal Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center and O\u2019Donnell School of Public Health, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Department of Dermatology, Division of Cardiology, Cardio-Dermatology and Cardio-Rheumatology Program, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Prussick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, George Washington University School of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Division of Medicine, Probity Medical Research, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Liu","sequence":"additional","affiliation":[{"name":"Bellevue Dermatology, Bellevue, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Glick","sequence":"additional","affiliation":[{"name":"GSI Clinical Research, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya M.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran E.","family":"Cook-Bolden","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, Department of Dermatology, New York, New York"},{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wallace","sequence":"additional","affiliation":[{"name":"Cherry Hills Dermatology, Englewood, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Garshick","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Department of Dermatology, New York University Langone Health, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 O.","family":"Alem\u00e1n","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy S.","family":"Eakin","sequence":"additional","affiliation":[{"name":"National Psoriasis Foundation, Alexandria, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting, Annapolis, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"drv260001r1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"drv260001r2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week.","volume":"77","author":"Garshick","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"drv260001r3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/jamacardio.2024.2859","article-title":"Exploring the link between genetic predictors of cardiovascular disease and psoriasis.","volume":"9","author":"Ramessur","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"4","key":"drv260001r4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"drv260001r5","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients.","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"drv260001r6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00228-025-03898-4","article-title":"GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management-current evidence and future outlook.","volume":"81","author":"Atiquzzaman","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"issue":"17","key":"drv260001r7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1001\/jama.2025.13665","article-title":"Current and future medications for obesity treatment.","volume":"334","author":"Kushner","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"drv260001r8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity\u2013inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.","volume":"22","author":"Haberman","year":"2026","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"drv260001r9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention.","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"drv260001r10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications.","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell Metab"},{"issue":"19","key":"drv260001r11","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.jacc.2025.03.516","article-title":"Effects of tirzepatide in type 2 diabetes: individual variation and relationship to cardiometabolic outcomes.","volume":"85","author":"Aminorroaya","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"drv260001r12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity.","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"drv260001r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity.","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"issue":"1","key":"drv260001r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/ANNALS-25-01724","article-title":"Comparative gastrointestinal safety of dulaglutide, semaglutide, and tirzepatide in adults with type 2 diabetes.","volume":"179","author":"Crisafulli","year":"2026","journal-title":"Ann Intern Med"},{"issue":"21","key":"drv260001r15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"},{"issue":"1","key":"drv260001r16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00011-025-02140-2","article-title":"The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.","volume":"74","author":"Buonanno","year":"2025","journal-title":"Inflamm Res"},{"issue":"4","key":"drv260001r17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"drv260001r18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"drv260001r19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"drv260001r20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"drv260001r21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity.","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"drv260001r22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes.","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"drv260001r23","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity.","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"11","key":"drv260001r24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"drv260001r25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"2","key":"drv260001r26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"drv260001r27","first-page":"6","article-title":"Phase 3 ESSENCE trial: semaglutide in metabolic dysfunction-associated steatohepatitis.","volume":"20","author":"Alkhouri","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"drv260001r28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial.","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"10019","key":"drv260001r29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"drv260001r30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis.","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"drv260001r31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity.","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"drv260001r32","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf116.0511","article-title":"The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis.","author":"Sasaki","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"drv260001r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"2","key":"drv260001r34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials.","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"issue":"9","key":"drv260001r35","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association.","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"drv260001r36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"drv260001r37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"drv260001r38","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials.","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"drv260001r39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease.","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"drv260001r40","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology.","volume":"86","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"drv260001r41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/bjd\/ljaf346","article-title":"Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.","volume":"194","author":"Olbrich","year":"2026","journal-title":"Br J Dermatol"},{"issue":"1","key":"drv260001r42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review.","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"key":"drv260001r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100181","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.","volume":"15","author":"Mozaffarian","year":"2025","journal-title":"Obes Pillars"},{"issue":"9","key":"drv260001r44","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jama.2025.11153","article-title":"Managing adverse effects of incretin-based medications for obesity.","volume":"334","author":"Kushner","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"drv260001r45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"issue":"1","key":"drv260001r46","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility.","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"issue":"6","key":"drv260001r47","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis.","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"issue":"2","key":"drv260001r48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis.","volume":"179","author":"Ko","year":"2026","journal-title":"Ann Intern Med"},{"issue":"1","key":"drv260001r49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes.","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"issue":"9","key":"drv260001r50","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis.","volume":"143","author":"Natividade","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"10296","key":"drv260001r51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"drv260001r52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11606-022-07726-8","article-title":"Glucose-lowering agents and the risk of hypoglycemia: a real-world study.","volume":"38","author":"Lyu","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"1","key":"drv260001r53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/oby.23910","article-title":"Proportion of caloric restriction-induced weight loss as skeletal muscle.","volume":"32","author":"Heymsfield","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"drv260001r54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial.","volume":"15","author":"Petkovic-Dabic","year":"2025","journal-title":"Biomolecules"},{"issue":"3","key":"drv260001r55","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"drv260001r56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2013a randomized placebo-controlled trial.","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"drv260001r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.106941","article-title":"Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?","volume":"164","author":"Nicolau","year":"2025","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"drv260001r58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ced\/llaf473","article-title":"Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study.","volume":"51","author":"Nicolau","year":"2026","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"drv260001r59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity.","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"drv260001r60","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study.","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"drv260001r61","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"drv260001r62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal ?d T-cell number: a prospective case-series study.","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"issue":"8","key":"drv260001r63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308533","article-title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.","volume":"19","author":"Karacabeyli","year":"2024","journal-title":"PLoS One"},{"issue":"12","key":"drv260001r64","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review.","volume":"39","author":"Paschou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"drv260001r65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13578-025-01486-8","article-title":"Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune\/autoinflammatory diseases.","volume":"15","author":"Deng","year":"2025","journal-title":"Cell Biosci"},{"key":"drv260001r66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3899\/jrheum.2025-0531","article-title":"What clinicians need to know about glucagon-like peptide 1 agonists.","volume":"52","author":"da Silva","year":"2025","journal-title":"J Rheumatol"},{"issue":"1","key":"drv260001r67","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103936","article-title":"Impact of GLP-1 analogues on immune-mediated inflammatory diseases: a systematic review.","volume":"25","author":"Birda","year":"2026","journal-title":"Autoimmun Rev"},{"issue":"6","key":"drv260001r68","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.","volume":"316","author":"Salazar","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"drv260001r69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdcr.2024.10.012","article-title":"Semaglutide-induced fixed drug eruption.","volume":"56","author":"Talasila","year":"2024","journal-title":"JAAD Case Rep"},{"key":"drv260001r70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103453","article-title":"Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: a real-world evidence study.","volume":"155","author":"Lee","year":"2025","journal-title":"J Autoimmun"},{"key":"drv260001r71","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.44343","article-title":"Dipeptidyl peptidase-4 inhibitors associated with lower psoriatic disease risk in type 2 diabetes: a 13-year nationwide cohort study with mechanistic validation.","volume":"105","author":"Hung","year":"2025","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"drv260001r72","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92454","article-title":"Hair loss associated with glucagon-like peptide-1 (GLP-1) receptor agonist use: a systematic review.","volume":"17","author":"Alsuwailem","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"drv260001r73","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study.","volume":"92","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"drv260001r74","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jacc.2015.12.058","article-title":"Incretin-based therapy for diabetes: what a cardiologist needs to know.","volume":"67","author":"Waldrop","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"drv260001r75","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review.","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"5","key":"drv260001r76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106645","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of infections: a systematic review and meta-analysis.","volume":"91","author":"Han","year":"2025","journal-title":"J Infect"},{"issue":"5","key":"drv260001r77","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review.","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf"},{"issue":"21","key":"drv260001r78","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects.","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"issue":"14","key":"drv260001r79","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines.","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"drv260001r80","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1007\/s12325-025-03257-w","article-title":"GLP-1 receptor agonists, DPP-4 inhibitors and the skin\u2014diabetes meets dermatology: a brief narrative review.","volume":"42","author":"Pantazopoulos","year":"2025","journal-title":"Adv Ther"},{"issue":"1","key":"drv260001r81","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis.","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"issue":"17","key":"drv260001r82","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis.","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"drv260001r84","doi-asserted-by":"publisher","DOI":"10.1177\/24755303251337020","article-title":"Practical recommendations on cardiovascular risk evaluation in patients with psoriasis and psoriatic arthritis for dermatologists, rheumatologists, and primary care physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network.","author":"Sheth","year":"2025","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"drv260001r85","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions.","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"2","key":"drv260001r86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"Compounded GLP-1 and dual GIP\/GLP-1 receptor agonists: a statement from the American Diabetes Association.","volume":"48","author":"Neumiller","year":"2025","journal-title":"Diabetes Care"},{"issue":"20","key":"drv260001r87","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1001\/jama.2025.15841","article-title":"Medicare part d coverage and costs for glucagon-like peptide-1 receptor agonists.","volume":"334","author":"Klebanoff","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"drv260001r88","doi-asserted-by":"publisher","first-page":"569","DOI":"10.18553\/jmcp.2023.29.5.569","article-title":"Medications for obesity management: effectiveness and value.","volume":"29","author":"Atlas","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"drv260001r89","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70247","article-title":"Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis.","author":"Morrow","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"drv260001r83","unstructured":"Eli Lilly and Co. Lilly\u2019s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind phase 3b trial for adults with active psoriatic arthritis and obesity or overweight. January 8, 2026. Accessed January 8, 2026. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2848173\/jamadermatology_sheth_2026_rv_260001_1780333329.8186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:00:39Z","timestamp":1781708439000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2848173"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0859","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}